Advanced Search

 

Study ID Status Title Patient Level Data
PHX111427 Completed A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects
PIK111051 Terminated A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients with Solid Tumors or Lymphoma Study Listed on ClinicalStudyDataRequest.com
PIR104776 Completed Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) A Double-blind, Placebo-controlled Study
PIR104777 Completed Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Open-Label, Uncontrolled, Long-term Study-
PIR109164 Terminated Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) - A Placebo-controlled, Single-Blind Comparative Study - Study Listed on ClinicalStudyDataRequest.com
PKI108574 Terminated A randomized, double blind, placebo controlled study to explore the antidepressant properties of P38a Kinase inhibitor GW856553X 15mg compared to PBO in Subjects with Major Depressive Disorder exhibiting symptoms of loss of energy and interest and psychomotor retardation, for a six week treatment period Study Listed on ClinicalStudyDataRequest.com
PKM5053 Completed A repeated dose study to assess the pharmacokinetic profiles and the safety of Org31540/SR90107A by subcutaneous administration of 0.75, 1.5, 2.5, and 3.0mg to Japanese healthy elderly subjects
PLK107427 Completed A Phase I Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of [GSK461364], a Polo-like Kinase 1 (PLK1) Inhibitor, in Adult Subjects with Advanced Solid Tumor or Non-Hodgkins Lymphoma Study Listed on ClinicalStudyDataRequest.com
PM1111138 Completed A double-blind, placebo-controlled, parallel group study to evaluate the effects of two regimens of GW856553, over a period of 3 month, on in-vivo macrophage activity, as assessed by FDG-PET/CT imaging, in the carotid arteries and aorta of subjects with established atherosclerosis Study Listed on ClinicalStudyDataRequest.com
PMK103351 Completed A 28-day, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steady-state pharmacokinetics of SB-681323 (7.5 mg) in subjects with coronary heart disease (CHD) undergoing elective percutaneous coronary interventions (PCI)
POP5108 Completed A repeated dose pharmacokinetic study in healthy volunteers to compare 1.5 mg of fondaparinux sodium in subjects with a low (35 to 50 kg) body weight (LBW) to 2.5 mg of fondaparinux sodium in subjects with standard (60 to 100 kg) body weight (SBW)
PREV123 Completed Multicentre randomised trial comparing two strategies for the episodic use of valaciclovir, alone or combined with suppressive treatment in immunocompetent patients with recurrent genital herpes
PRO10017 Completed A Study to Investigate Whether There is a Pharmacokinetic Interaction Between Amprenavir and Ritonavir Following Their Co-Administration to Healthy Subjects.
PRO10018 Completed A Study to Investigate Whether There is a Pharmacokinetic Interaction Between Amprenavir and an Oral Contraceptive Following Their Co-Administration to Healthy Females.
PRO10022 Completed A Study to Investigate the Degree of Pharmacokinetic Interaction Between Amprenavir and Ritonavir Following Their Co-Administration to Healthy Subjects.
PRO10023 Completed A Study to Further Investigate the Degree of Pharmacokinetic Interaction Between Amprenavir and Ritonavir Following Their Co-Administration to Healthy Subjects.
PRO10024 Completed A descriptive study to investigate the pharmacokinetic interaction between amprenavir and ritonavir following their co-administration in subjects with HIV-1 infection.
PRO30010 Completed Amprenavir (141W94) Open Label Protocol for Subjects with HIV-1 Infection Who Have Experienced Treatment Failure or Are Intolerant to Previous Protease Inhibitor Therapy.
PRO30011 Completed An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor-Experienced Subjects with HIV-1 Infection Who are Failing Their Current Antiretroviral Treatment Regimen.
PRO30012 Completed An Open-Label Study to Evaluate the Safety and Tolerance of Amprenavir (141W94) Combination Therapy in Protease Inhibitor Experienced Subjects Who Are Intolerant (Hyperlipidemia With or Without lipodystrophy) But Not Failing Their Current Protease Inhibitor Therapy
PRO30013 Completed Amprenavir (141W94) Open Label Study for Subjects with HIV infection who are Failing or are Intolerant to Previous Protease Inhibitor Therapy.
PRO30017 Completed A Phase III Randomised Multicentre Open-Label Study to Evaluate the Efficacy of AGENERASE (AGN; 600mg BID) in Combination with Low Dose Ritonavir (RTV; 100mg BID) Versus Other Protease Inhibitors (PIs) in HIV-Infected PI-Experienced Adults Over a 16 Week Period: Final Analyses of PRO30017…
PRO30017_1 Completed A Phase III randomised multicentre open-label study to evaluate the efficacy of AGENERASE (AGN; 600mg BID)/Ritonavir (RTV; 100mg BID) versus continued protease inhibitors (PIs) in HIV-1 Infected PI-experienced adults with evidence of HIV resistance to all approved PIs other than amprenavir: Fina ...
PROA1001 Completed A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 141W94 (Protease Inhibitor).
PROA1002 Completed The Pharmacokinetics and Pharmacodynamics of a Phase I/II Trial to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of Amprenavir After Multiple Dosing in Subjects With HIV InfectionExtensive searching has revealed that no clinical study report is available for this study…

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.